Annals of the Rheumatic Diseases (ARD) is an international peer-reviewed journal committed to promoting the highest standards of scientific exchange and education. It covers all aspects of rheumatology, which includes the spectrum of musculoskeletal conditions, arthritic disease, and connective tissue disorders. ARD publishes basic, clinical, and translational scientific research. Concise scientific communication is encouraged and peer-reviewed proceedings of international meetings are featured. ARD is the official journal of EULAR. * The purpose of this podcast is to educate and to inform. The content of this podcast does not constitute medical advice and it is not intended to function as a substitute for a healthcare practitioner’s judgement, patient care or treatment. The views expressed by contributors are those of the speakers. BMJ does not endorse any views or recommendations discussed or expressed on this podcast. Listeners should also be aware that professionals in the field may have different opinions. By listening to this podcast, listeners agree not to use its content as the basis for their own medical treatment or for the medical treatment of others.
In this podcast, Dr. Paul Studenic speaks to Dr. Sofia Ramiro and Prof. Robert Landewé both engaged in clinical work in the Zuyderland Medical Center ...
Statins are some of the most commonly prescribed cholesterol-lowering drugs. They act by inhibiting HMG-CoA reductase, the main enzyme in the synthesi...
In this podcast recorded at the ACR meeting 2019, Dr. Caroline Ospelt speaks to Prof. Anca Catrina and Dr. Aase Hensvold both of the Division of Rheum...
Dr. Felice Rivellese from the Center of Experimental Medicine and Rheumatology at the Queen Mary University in London discusses the results of his pre...
This randomised, double-blind, placebo-controlled trial by Kroon et al has demonstrated a substantial improvement in painful hand OA with signs of inf...
Atul Deodhar, from the Oregon Health & Science University, provides an overview of recent clinical trial results in the area of seronegative Spondylar...
TULIP 2: Efficacy and Safety of Anifrolumab in Patients with Moderate to Severe Systemic Lupus Erythematosus: Results of the Second Phase 3 Randomized...
TULIP 1: A Phase 3 Randomized Controlled Trial of Anifrolumab in Patients with Moderate to Severe Systemic Lupus Erythematosus In this first phase 3 t...
The paper discussed in this podcast provides an approach, using Capture Hi-C data, to link genetic associations to potential causal genes and assess t...
The highlights of the latest update of the EULAR recommendations for the management of systemic lupus erythematosus (SLE), based on emerging new evide...